Headquartered in Latham, NY Fiscal year ends May NASDAQ: ANGO angiodynamics.com
AngioDynamics is a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients. The company operates through two segments: Med Tech, which includes the Auryon peripheral atherectomy platform, a thrombus management platform led by AlphaVac and AngioVac mechanical thrombectomy devices, and the NanoKnife irreversible electroporation (IRE) platform for cancer treatment; and Med Device, which encompasses a broader portfolio of vascular access and other medical devices. The company sells its products primarily in the United States with a growing international presence. AngioDynamics maintains a debt-free balance sheet and is in the midst of a strategic transformation focused on shifting its revenue mix toward higher-growth, higher-margin Med Tech products, which now represent approximately 49% of total sales. The company is also pursuing regulatory expansion of its NanoKnife platform into benign prostatic hyperplasia treatment through the FDA IDE-approved RELIEF study. Updated
The quarterly loss came in at a third of what analysts expected as gross margin expanded 410 basis points to 59.4%. Full-year sales guidance of $336 million to $341 million stays intact ahead of Eric Honroth taking over as CEO in November.
Friday's top analyst upgrades and downgrades included Applied Materials, Autodesk, Bank of America, BP, Broadcom, Micron Technology, Morgan Stanley and Western Digital.
Wednesday's top analyst upgrades and downgrades included Analog Devices, Apple, Best Buy, Dell Technologies, Dollar Tree, Ford, General Electric, General Motors, HP, Medtronic and Zscaler.
AngioDynamics is a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients.
The Wall Street consensus 12-month price target for ANGO is $19.75.
